NFS1 deficiency can trigger PANoptosis and shows synergistic effects by increasing ROS levels with oxaliplatin treatment, and NFS1 inhibition is a promising strategy to improve the outcome of platinum-based chemotherapy in CRC [9]. The gene discussed is NFS1; the disease is colorectal carcinoma.